Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents

Citation for published version:
Montanaro, G, Bertinaria, M, Rolando, B, Fruttero, R, Lucas, C, Dorward, DA, Rossi, AG, Megson, IL & Gasco, A. 2013. 'Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents' Bioorganic and Medicinal Chemistry, vol 21, no. 7, pp. 2107-2116. DOI: 10.1016/j.bmc.2013.01.009

Digital Object Identifier (DOI):
10.1016/j.bmc.2013.01.009

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Bioorganic and Medicinal Chemistry

Publisher Rights Statement:
Open Access funded by Wellcome Trust

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents

Gabriele Montanaro, Massimo Bertinaria, Barbara Rolando, Roberta Frutteroa, Christopher D. Lucusb, David A. Dorwardb, Adriano G. Rossib, Ian L. Megsonc, Alberto Gascoa

**Abstract**

Neutrophils play a pivotal role in the pathophysiology of multiple human inflammatory diseases. Novel pharmacological strategies which drive neutrophils to undergo programmed cell death (apoptosis) have been shown to facilitate the resolution of inflammation. Both the cyclin-dependent kinase inhibitor (CDKi) R-roscovitine and nitric oxide (NO) have been shown to enhance apoptosis of neutrophils and possess pro-resolution of inflammation properties. In order to search for new multi-target pro-resolution derivatives, here we describe the design, synthesis and investigation of the biological potential of a small series of hybrid compounds obtained by conjugating R-roscovitine with two different NO-donor moieties (compounds 2, 9a, 9c). The synthesized compounds were tested as potential pro-resolution agents, with their ability to promote human neutrophil apoptosis evaluated. Both compound 9a and 9c showed an increased pro-apoptotic activity when compared with either R-roscovitine or structurally related compounds devoid of the ability to release NO (des-NO analogues). Inhibition of either NO-synthase or soluble guanylate cyclase did not affect the induction of apoptosis by the R-roscovitine derivatives, similar to that reported for other classes of NO-donors. In contrast the NO scavenger PTIO prevented the enhanced apoptosis seen with compound 9a over R-roscovitine. These data show that novel compounds such as CDKi-NO-donor hybrids may have additive pro-resolution of inflammation effects.

**1. Introduction**

Inflammation is the host response to tissue injury or infection, aimed at restoring damaged tissue to homeostasis. Following injury a variety of endogenous mediators are released which mediate the cardinal signs of inflammation: heat, redness, swelling, and pain. Vasoactive amines, lysosomal enzymes, cytokines, kinins, eicosanoids, clotting and fibrinolytic system products, nitric oxide (NO), and reactive oxygen species (ROS), are some of the important mediators involved. During an episode of acute inflammation a complex series of events occurs including the recruitment of leukocytes to the damaged tissue. Granulocytes (which comprise neutrophils, eosinophils and basophils) are the first leukocytes to be recruited, followed by monocyte/macrophage and lymphocyte infiltration into the inflamed tissue. The granulocytes are the body’s first line of innate immune defense and have the task of neutralizing the injurious stimulus.

After removal of the inciting inflammatory stimulus it is essential that granulocytes die by apoptosis, a programmed and non-inflammatory form of cell death, in order that resolution of inflammation can occur. Apoptotic granulocytes are rapidly removed from inflammatory sites by macrophage phagocytosis with consequent dampening of inflammation. Previously it was believed that, after removal of the cause of the injury, the resolution of inflammation was merely a passive process secondary to the catabolism of pro-inflammatory mediators. More recently, an increasing number of studies have demonstrated that the resolution of inflammation is an active process involving several cellular processes including apoptosis and phagocytic clearance of apoptotic cells that can be modulated by endogenous specialized pro-resolving mediators (SPM). These include cyclopentanone prostaglandins, lipoxins, resolvins, protectins/neuroprotectins, and maresins. When inflammation resolution fails, the granulocytes can die by necrosis, an alternative form of cell death that involves rupture of cellular membrane with consequent release of granulocyte histotoxic contents into the extracellular milieu. This can perpetuate inflammation leading to chronicity, with dysregulated granulocyte apoptosis being involved in the pathogenesis of several human inflammatory diseases. The development of pharmacological agents or strategies capable of selectively increasing granulocyte apoptosis is a potential new therapeutic strategy to reduce both acute and chronic inflammatory diseases.
Scheme 1. Preparation of derivative 2. Reagents: (i) 4-nitroxybutirric acid, EDC, DMAP, dry Pyr, 4 h, rt.

Scheme 2. Preparation of derivatives 9a–d. Reagents and conditions: (i) H$_2$SO$_4$, H$_2$O/MeOH, 3 h, Δ; (ii) benzylmercaptane, DIPEA, EtOH, 4 h, Δ; (iii) 2-bromopropane, K$_2$CO$_3$, DMSO, 12 h, 50 °C; (iv) R-(2)-amino-1-butanol, nBuOH, 5 days, Δ; (v) mCPBA, CH$_2$Cl$_2$, 3 h, rt; (vi) 12, 14, 16 or 18, Et$_3$N, MeOH, 5 days, 40 °C.
inflammation. The use of small molecule inhibitors of the serine/threonine cyclin-dependent kinases (CDKs) is one of the most promising strategies. There are at least 13 different CDK isoenzymes so far identified, and 25 different cyclins, the binding partners necessary for CDK activation. CDKs play essential functions in many biological processes including cell division, transcription, neuronal cell physiology, pain signaling, apoptosis, and RNA splicing.

A variety of CDK inhibitor drugs have been described from different chemical classes including purines, pyrimidines, flavones, pyridopyrimidines, oxindoles, quinazolines and pyrazoles. R-Roscovitine 1, a 2,6,9-trisubstituted purine, is one of the most studied. It is an inhibitor of CDK 1, 2, 5, 7 and 9 isoforms and has been widely investigated as a potential anticancer drug. The purine portion of the inhibitor binds to the adenine binding pocket of the enzyme, even if rotated with respect to the original ATP conformation. The crystal structure of the CDK2 and R-rroscovitine complex is known, with the drug binding to the ATP binding pocket of the enzyme through hydrophobic and Van der Waals contacts, as well as hydrogen bonds between N(6) and N(7) of the purine ring and Leu83 of the enzyme. Another hydrogen bond involves O(1) of the aminobutanol lateral chain that binds to an area occupied by the ribose in the CDK2/ATP complex. Since R-rroscovitine is able to enhance neutrophil apoptosis it also has a potential application as a pro-resolving anti-inflammatory agent.

2. Results and discussion

2.1. Chemistry

The pro-drug 2 was easily obtained by coupling 1 with 4-nitrooxybutirric acid, under the action of 1-ethyl-3-(3-dimethylaminopropyl)/carbodiimide (EDC), in the presence of catalytic amount of 4-dimethylaminopyridine (DMAP) in pyridine solution (Scheme 1). All the remaining products were synthesized starting from 6-benzylthio-2-ido-9-isopropyl-9H-purine 6 (Scheme 2). This intermediate was already known in literature, but we prepared it through a partly modified route. The acetylated ribosyl group present in the guanosine derivative 3 was removed by the action of sulfuric acid to afford the already described 6-chloro-2-iodopurine 4. Nucleophilic displacement of the chloride with benzylmercaptane in the presence of diisopropylethylamine (DIPEA) led to the 2-ido-6-benzylthio substituted purine 5. The subsequent reaction with 2-bromopropane in DMSO in the presence of K2CO3 gave the N(9) regioselective alkylation, with resulting production of 6. This intermediate, treated in refluxing nBuOH with pure R-(2)-amino-1-butanol, yielded the expected R-rroscovitine thioanalogue 7.
product was oxidized to the corresponding sulfonyl derivative 8 using m-chloroperbenzoic acid (mCPBA). Finally, 8 was treated with the appropriate benzyl amine derivative (12, 14, 16, 18) in methanol solution in the presence of Et3N to give the target compounds 9a-d. The preparation of the substituted benzyamines used in the reaction is outlined in Scheme 3. All the products were synthesized starting from Boc-protected p-hydroxybenzylamine 10. Compounds 12, 18, were obtained following nucleophilic displacement by 10 of the bromine present in 11 and 17, and subsequent Boc-deprotection with trifluoroacetic acid in CH2Cl2. In a similar manner 14 was prepared using the tosylate 13. Finally, 10, treated with 4-hydroxymethyl furoxan-3-carboxyamidine (15), in the presence of PPh3 and disopropyl azodicarboxylate (DIAD) in THF solution (Mitsunobu procedure), afforded 16.

2.2. Biological activity

All the NO-donor R-roscovitine derivatives, and the related des-NO-reference compounds, were tested for their ability to induce apoptosis in neutrophils isolated from peripheral blood of healthy
viable (solid line, □), apoptotic (dotted line, ●) and necrotic (dashed line, △) neutrophils induced by treatment with 10 μM R-roscovitine (a) (panel a), compounds 2 (panel b), 9a (panel c) and 9c (panel d). Results expressed as mean ± SEM, n = 3.

Figure 2. R-Roscovitine and NO-donor R-roscovitine compounds induce neutrophil apoptosis in a time-dependent manner. Time course demonstrating the percentage (%) of viable (solid line, □), apoptotic (dotted line, ●) and necrotic (dashed line, △) neutrophils induced by treatment with 10 μM R-roscovitine (a) (panel a), compounds 2 (panel b), 9a (panel c) and 9c (panel d). Results expressed as mean ± SEM, n = 3.

Analysis of the concentration–response profiles show that all the new synthesized compounds 2, 9a–d enhanced neutrophil death by inducing apoptosis in a concentration-dependent manner (Fig. 3), in the range 0.3–20 μM. Both compounds 9a and 9b were significantly more potent than the lead. Moreover, the organic nitrate 9a was markedly more active than its des-NO model 9b in the 1–10 μM range, suggesting an involvement of NO in its additional pro-apoptotic action. Also the furoxan hybrid compounds 9c and its furazan analogue 9d show a better dose–response profile with respect to R-roscovitine, and, in addition, 9c is significantly more active than its des-NO furazan reference. The pro-drug 2 also enhanced neutrophil death by inducing apoptosis in a concentration-dependent manner, but it was a slightly less potent than R-roscovitine. This behavior could be explained by the possibility that the product, over the time of the experiments, acts largely as an intact drug, which should be less active than the lead, in spite of the presence of NO-donor moiety, following the masking of the OH group in the lateral chain. Previous studies with other NO-donor compounds (SIN-1, GEA-3162) showed that NO-donor triggered neutrophil apoptosis is cGMP-independent and involves the concurrent generation of superoxide anion O₂⁻ that could rapidly react with NO to form the powerful oxidizing agent peroxynitrite (ONOO⁻). Nevertheless, it is not possible to exclude a partial involvement of NO synthase (NOS), did not modify the behavior of R-roscovitine, compounds 2, 9a or 9c, suggesting that their pro-apoptotic effect is not related to iNOS expression or regulation (Fig. 4a). Similarly, the prior administration of ODQ (10 μM), a well known inhibitor of soluble guanylate cyclase (sGC), did not affect the induction of apoptosis (Fig. 4b), excluding involvement of sGC, and confirmed the findings previously reported for other classes of NO-donors. To further investigate the dependency upon NO release for the increased apoptosis observed with the NO-donor containing compounds we co-incubated neutrophils with PTIO, a NO scavenger (Fig. 4c). As expected the presence of PTIO did not affect constitutive neutrophil apoptosis, gliotoxin-induced apoptosis or R-roscovitine-induced apoptosis. However PTIO caused a
concentration-dependent inhibition of apoptosis when co-incubated with compound 9a. The rate of apoptosis was not different (p > 0.05) between R-roscovitine and compound 9a in the presence of >1 mM PTIO, suggesting that the additional apoptosis induced by compound 9a over R-roscovitine was dependent upon NO.

3. Conclusion

Basing on the known pro-resolution activity of R-roscovitine, novel NO-donor R-roscovitine multi-target compounds were prepared with a good yield. The biological results indicate that the new NO-donor R-roscovitine compounds described in the present work are endowed with an enhanced roscovitine-like capacity of inducing neutrophil apoptosis, likely involving inhibition of CDKs as well as release of NO. In particular, derivatives 9a and 9c were found to be significantly more biologically active than the lead, an effect reduced in their des-NO derivatives 9b and 9d, or by co-incubating 9a and 9c with an NO scavenger. This suggests a crucial involvement of the release of NO from the NO-mimetic compounds in their enhanced biological activity.

4. Experimental

4.1. Reagents and general methods

All the compounds were routinely checked by 1H and 13C NMR (Bruker Avance 300) at 300 and 75 MHz, respectively, and mass spectrometry (Finnigan-Mat TSQ-700). The following abbreviations are used to indicate the peak multiplicity: s = singlet, d = doublet, t = triplet, m = multiplet, Fx = furoxan ring, Fz = furazan ring. Melting points of unpublished solid derivatives were measured with a capillary apparatus (Buchi B-540). Flash column chromatography was performed on silica gel (Merck Kieselgel 60, 230–400 mesh ASTM) using the reported eluents. Thin layer chromatography (TLC) was carried out on 5 cm × 20 cm plates (Fluka) with a 0.2 mm layer thickness. Purity of final compounds was
4.2.1. (2,4,5-oxadiazolo-[4,3-d]dihydrate, PBS 10X, NSerum Albumine (BSA), sterile DMSO, sodium citrate tribasic PAA. Sterile water and saline were from Baxter. Bovine crude residue was purified by flash chromatography eluting with PE/CH2Cl2 1:1 gradient to CH2Cl2 to obtain the title product as a white solid. MS/Cl (isobutane): \[M+1\]^+ 355. 1H NMR (CDCl3): 4.94 (d br, 1H, CHN), 4.56 (s, 2H, C), 7.38–7.35 (m, 1H, CH2O), 1.72–1.49 (m, 8H, CH2CH2 and CH(CH3)2), 1.00 (t, 3H, CH3CH2). 13C NMR (CDCl3): δ 160.0, 154.9, 152, 138.9, 134.6, 128.5, 127.7, 127.3, 114.7, 68.2, 56.2, 46.4, 44.4, 25.0, 22.6, 22.5, 10.9. Spectral data are in agreement with those reported in literature.25b

4.2.2. (2R)-[6-Benzylamino-9-isoxylo-8-yIamin0-2-ylamino]butyl 4-[(nitroxy)-butanoate (2)

Compound 2 (80 mg, 0.225 mmol) was solubilized in dry pyridine (10 mL). 4-Nitroxybutyric acid26 (74 mg, 0.495 mmol), EDC (52 mg, 0.27 mmol) and DMAP (cat.) were added and the mixture was stirred at room temperature for 4 h. The mixture was treated with HCl 1 N, extracted with CH2Cl2 (3 × 15 mL) and the combined organic phases were washed with HCl 1 N, extracted with CH2Cl2 (3 × 3 mL), brine (20 mL), dried (Na2SO4), filtered and evaporated in vacuo to obtain a yellow oil. The crude product was purified by flash chromatography eluting with PE/CH2Cl2 1:1 gradient to CH2Cl2 to obtain the desired product as a white solid (500 mg, 50% yield). MS/Cl (isobutane): [M+1]^+ 411. 1H NMR (CDCl3): δ 7.93 (s, 1H, H2), 7.51 (d, 2H, HAr 2), 7.34–7.21 (m, 3H, HAr 3,4,5), 4.90–4.81 (m, 1H, CH2CH2), 4.56 (s, 2H, CH2Ph), 1.61–1.57 (m, 6H, CH2CH2). 13C NMR (CDCl3): δ 161.5, 148.9, 140.0, 137.2, 131.1, 129.5, 128.4, 127.4, 118.2, 47.5, 33.3, 22.7. 1H NMR and 13C NMR are identical to the spectra reported in literature.28

4.2.4. 6-Benzthio-2-iodo-9-isopropyl-9H-purine (6)

Compound 5 (900 mg, 2.44 mmol) was solubilized in DMSO (20 mL), K2CO3 (1.01 g, 7.32 mmol) and 2-bromopropane (574 μL, 6.11 mmol) were added and the mixture was stirred at 50 °C overnight. The mixture was treated with water (50 mL), extracted with AcOEt (3 × 60 mL), dried (Na2SO4), filtered and evaporated in vacuo to obtain a yellow oil. The crude product was purified by flash chromatography eluting with PE/CH2Cl2 1:1 gradient to CH2Cl2 to obtain the desired product as a white solid (500 mg, 50% yield). MS/Cl (isobutane): [M+1]^+ 411. 1H NMR (CDCl3): δ 7.93 (s, 1H, H2), 7.51 (d, 2H, HAr 2), 7.34–7.21 (m, 3H, HAr 3,4,5), 4.90–4.81 (m, 1H, CH2CH2), 4.56 (s, 2H, CH2Ph), 1.61–1.57 (m, 6H, CH2CH2). 13C NMR (CDCl3): δ 161.5, 148.9, 140.0, 137.2, 131.1, 129.5, 128.4, 127.4, 118.2, 47.5, 33.3, 22.7. 1H NMR and 13C NMR are identical to the spectra reported in literature.28

4.2.5. (2R)-[6-Benzylsulfonyl-9-isopropyl-9H-purin-2-ylamin0-butanol (7)

Compound 6 (0.5 g, 1.22 mmol) was suspended in n-butanol (20 mL). (R)-2-Amino-1-butanol was added (434 mg, 4.88 mmol) and the reaction was refluxed for 5 days. The solvent was evaporated in vacuo by applying an oil pump and the crude residue was purified by flash chromatography eluting with CH2Cl2 gradient to CH2Cl2/MeOH 1:5 to obtain pure product as a colourless oil (340 mg, yield 75%). MS/Cl (isobutane): [M+1]^+ 372. 1H NMR (CDCl3): δ 7.67 (s, 1H, H8), 7.43 (d, 2H, HAr 2), 7.29–7.26 (m, 3H, HAr 3,4,5), 5.20 (d br, 1H, CH2OH), 4.70–4.63 (m, 1H, CH(2CH2)), 4.56 (s, 2H, CH2Ph), 4.02–3.90 (m, 1H, CHNH), 3.81 (m, 1H, CH2OH), 3.69 (m, 1H, CH2OH), 1.80–1.53 (m, 8H, CH2CH2 and CH(2CH2)), 1.02 (t, 3H, CH3CH2). 13C NMR (CDCl3): δ 160.9, 158.7, 149.8, 137.6, 137.4, 129.0, 128.4, 127.1, 125.5, 66.5, 55.9, 46.8, 32.7, 24.80, 22.45, 22.39, 10.8.

4.2.6. (2R)-[6-BenzyIsulfonlfyI-9H-purin-2-ylamin0-butanol (8)

Derivative 7 (170 mg, 0.45 mmol) was solubilized in CH2Cl2 (10 mL), the mixture was cooled to 0 °C and m-CBPA was added (340 mg, 1.35 mmol). The mixture was stirred at room temperature for 3 h, then diluted with water. The two layers were washed and the water phase was extracted with fresh CH2Cl2 (15 mL). The combined organic phases were washed with NaHCO3 5% (2 × 10 mL), water (10 mL), brine (10 mL), dried (Na2SO4), filtered and evaporated in vacuo. The crude product was purified eluting with CH2Cl2 gradient to CH2Cl2/MeOH 2% to obtain the title product as a white solid (590 mg, 50% yield). MS/Cl (isobutane): [M+1]^+ 411. 1H NMR (CDCl3): δ 7.93 (s, 1H, H2), 7.51 (d, 2H, HAr 2), 7.34–7.21 (m, 3H, HAr 3,4,5), 4.90–4.81 (m, 1H, CH2CH2), 4.56 (s, 2H, CH2Ph), 1.61–1.57 (m, 6H, CH2CH2). 13C NMR (CDCl3): δ 161.5, 148.9, 140.0, 137.2, 131.1, 129.5, 128.4, 127.4, 118.2, 47.5, 33.3, 22.7. 1H NMR and 13C NMR are identical to the spectra reported in literature.28
product as a yellow oil (82 mg, yield 45%). Derivative 8 was stored at -18 °C or immediately reacted to avoid a possible decomposition. MS/Cl (isobutane): [M+1]+ 404. 1H NMR (CDCl3): δ, 7.96 (s, 1H, H5), 7.74–7.26 (m, 5H, HAr), 5.95 (d br, 1H, NH(2)), 4.84 (s, 2H, CH2Ph), 4.79–4.68 (m, 1H, CH(CH3)2), 4.04 (s br, 1H, CHNH), 3.82–3.80 (m, 1H, CH2OH), 3.72–3.66 (m, 1H, CH2OH), 1.76–1.58 (m, 8H, CH2CH3 and CH(CH3)2), 0.99 (t, 3H, CH3C), 13C NMR (CDCl3): δ, 158.5, 156.0, 153.3, 142.3, 131.7, 129.6, 129.0, 126.5, 123.3, 64.2, 59.4, 53.5, 47.4, 24.3, 22.2, 22.0, 10.7.

4.2.7. General procedure for preparation of 9a–d

Compound 8 (107 mg, 0.265 mmol) was solubilized in EtOH (10 mL). Triethylamine (111 µL, 0.795 mmol) and the correct amino derivatives (12, 14, 16 or 18) (1.5 equiv) were added, and the mixture was stirred at 40 °C for 5 days. The solvent was evaporated in vacuo, dissolved in CH2Cl2 (30 mL), washed with water (2 × 20 mL), dried (Na2SO4), filtered and evaporated under reduced pressure. The crude residue was purified by flash chromatography eluting with CH2Cl2/ACOEt 6:4 gradient to 1:9 to obtain pure products. Derivatives 9a–d were stored at -18 °C.

4.2.7.1. (2R)-2-[[9-Isopropyl-6-[[4-[[3-(nitroxy)propoxy]benzyl]amino]-9H-purin-2-yl]amino]butanol (9a).

Pale yellow oil (yield 40%). MS/Cl (isobutane): [M+1]+ 474. δ, 7.36 (s, 1H, H5), 7.25 (d, 2H, HAr x 2), 6.79 (d, 2H, HAr x 2), 6.54 (s br, 1H, NH(6)), 5.20 (d br, 1H, NH(2)), 4.66–4.60 (m, 4H, CH2Ph and CH2ONO2), 4.58–4.54 (m, 1H, CH(CH3)2), 4.04 (m, 2H, CH2OH), 3.92–3.87 (m, 1H, CHNH), 3.82–3.77 (m, 1H, CH2OH), 3.65–3.59 (m, 1H, CH2OH), 3.21–3.13 (m, 2H, CH2CH3 and CH(CH3)2), 1.64–1.47 (m, 8H, CH2CH3 and CH(CH3)2), 0.99 (t, 3H, CH3C), 13C NMR (CDCl3): δ, 160.0, 157.8, 154.8, 150.2, 134.2, 131.9, 129.0, 114.7, 114.4, 70.0, 67.8, 63.5, 56.1, 46.3, 43.7, 26.9, 24.9, 22.7, 22.5, 10.9. HPLC purity (CH2CN/H2O + 0.1% TFA, 1/1): 98%. Elemental analysis for C23H34N6O3. Calculated: C, 52.66; H, 5.92; N, 25.21. Found: C, 52.48; H, 5.88; N, 25.24.

4.2.7.2. (2R)-2-[[9-Isopropyl-6-[[4-[[3-(methoxy)propoxy]benzyl]amino]-9H-purin-2-yl]amino]butanol (9b).

Pale yellow oil (yield 40%). MS/Cl (isobutane): [M+1]+ 443. δ, 7.23–7.20 (m, 4H, HAr x 2 and NH(6)), 6.78 (d, 2H, HAr x 2), 5.80 (s br, 1H, OH), 5.26 (d br, 1H, NH(2)), 4.64 (s br, 2H, CH2Ph), 4.56–4.47 (m, 1H, CH(CH3)2), 4.00 (t, 2H, CH2OH), 3.93–3.91 (m, 1H, CHNH), 3.77–3.73 (m, 1H, CH2OH), 3.64–3.61 (m, 1H, CH2OH), 3.51 (t, 2H, CH2OCH3), 3.31 (s, 3H, OCH3), 2.04–1.96 (m, 2H, CH2CH3 and CH(CH3)2), 1.62–1.41 (m, 8H, CH2CH3 and CH(CH3)2), 0.96 (t, 3H, CH3C). 13C NMR (CDCl3): δ, 159.9, 158.1, 154.8, 150.3, 153.4, 131.3, 129.2, 114.7, 113.9, 69.2, 66.5, 64.7, 58.6, 55.6, 46.2, 43.6, 29.5, 24.7, 22.6, 22.3, 10.9. HPLC purity (CH2CN/H2O + 0.1% TFA, 1/1): 99%. Elemental analysis for C23H32N6O3. Calculated: C, 62.42; H, 7.74; N, 18.99. Found: C, 62.48; H, 7.78; N, 18.85.

4.2.7.3. 4-[[4-[[1R]1-[[6-Hydroxymethyl]propyl]amino]-9-isopropyl-9H-purin-6-yl][amino]-benzyl]phenoxy][methy]furoxan-3-carboxamide (9c).

Yellow solid (yield 50%). MS/Cl (isobutane): [M+1]+ 512. Mp 136 °C dec. 1H NMR (CDCl3): δ, 7.76 (s, 1H, H5), 7.31 (d, 2H, HAr x 2), 6.98 (d, 2H, HAr x 2), 5.38 (s, 2H, Fx-CH2OPh), 4.67–4.60 (m, 3H, CH2Ph and CH(CH3)2), 3.94 (m, 1H, CHNH), 3.61 (m, 1H, CH2OH), 1.70–1.52 (m, 8H, CH2CH3 and CH(CH3)2), 0.96 (t, 3H, CH3C). 13C NMR (CDCl3): δ, 161.2, 158.6, 158.1, 156.6, 156.0, 152.1, 136.4, 134.3, 130.0, 116.1, 114.6, 111.8, 65.5, 62.7, 55.9, 47.9, 44.5, 25.5, 22.7, 22.6, 11.1. HPLC purity (CH2CN/H2O + 0.1% TFA, 1/1): 95%. Elemental analysis for C23H32N6O3.1H2O. Calculated: C, 53.53; H, 5.76; N, 24.42. Found: C, 53.65; H, 5.72; N, 24.10.
This intermediate was not further characterized but reacted immediately.

4.2.10. 4-[(4-(Aminomethyl)phenoxy)methyl]furazan-3-carboxamide (16)

Compound 10 (500 mg, 2.23 mmol) was solubilized in dry THF (50 mL). CAS 1609 (15) (534 mg, 3.34 mmol), produced by Cassel–Hoechst Co., and PPh3 (1.17 g, 4.46 mmol) were added. The mixture was cooled at 0°C, DIAD (877 µL, 4.46 mmol) was solubilized in dry THF (2 mL) and added dropwise. The mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure and the residue was solubilized in CH2Cl2 (50 mL). After 30 min sedimentation, the upper layer (containing PEP) was removed and 6 mL of dextran 6% (6 g in 100 mL 0.9% NaCl) was added with trifluoroacetic acid (2 mL) and stirred at room temperature for 3 h. The solvent was evaporated and the residue treated with water (45 mL) and extracted with AcOEt (2 × 50 mL). The water phase was added with Na2CO3 10% and newly extracted with AcOEt (4 × 40 mL). The combined organic phases were dried (K2CO3), filtered and evaporated in vacuo. The crude product was purified by flash chromatography eluting with CH2Cl2/MeOH 5% to obtain pure product as a yellow solid (400 mg, yield 67%). MS/CI (isobutane): [M+1]+ 265. Mp 145°C dec.

1H NMR (CD3OD): δ, 7.29 (d, 2H, HAr 3), 7.01 (d, 2H, HAr 2), 5.40 (s, 2H, Fz-CH2OPh), 3.75 (s, 2H, CH2Ph). This intermediate was not further characterized but reacted immediately.

4.2.11. 4-[(4-(Aminomethyl)phenoxy)methyl]furazan-3-carboxamide (18)

Compound 10 (500 mg, 2.23 mmol) was solubilized in dry CH2Cl2 (50 mL), DBU (490 µL, 3.34 mmol) and 4-(bromomethyl)-1,2,5-oxadiazole-3-carboxamide (17) (460 mg, 2.23 mmol) were added. The mixture was stirred at room temperature overnight, cooled at 0°C, added with trifluoroacetic acid (5 mL) and stirred at room temperature for 1 h. The solvent was evaporated under reduced pressure and the residue treated with water (40 mL) and extracted with AcOEt (2 × 50 mL). The water phase was added with Na2CO3 10% and extracted with fresh AcOEt (4 × 40 mL). The combined organic phases were washed with brine (60 mL), dried (Na2SO4), filtered and evaporated in vacuo. The crude product was purified by flash chromatography eluting with CH2Cl2/MeOH 5% to obtain pure product as a pale yellow oil (350 mg, yield 63%). MS/Cl (isobutane): [M+1]+ 249. 1H NMR (CD3OD + d6-DMSO): δ, 7.27 (d, 2H, HAr 3,5), 7.00 (d, 2H, HAr 2,6), 5.49 (s, 2H, Fz-CH2OPh), 4.58 (s br, 2H, CH2NH2), 3.72 (s, 2H, CH2Ph). This intermediate was not further characterized but reacted immediately.

4.3. Neutrophil culture and assessment of apoptosis

4.3.1. Cells isolation and culture

Neutrophils (>96% purity, with 1–4% contaminating eosinophils) were re-suspended at 5 × 10⁶/mL in IMDM containing penicillin (100 U/mL) and streptomycin (100 µg/mL) and supplemented with 0.1% w/v bovine serum albumin (BSA). Cells were cultured in flat-bottomed flexible 96-well Falcon polypropylene plates (final volume 150 µL each well) in a 5% CO2 atmosphere at 37°C and treated in duplicate with the corresponding compounds, added immediately prior to the addition of the other tested compounds, to avoid a possible interference of endogenous NOS and sGC.

4.3.2. Preparation of the drugs

All tested compounds were prepared in a 50 mM stock solution in sterile DMSO and diluted daily in IMDM as necessary. Wortmannin and PTIO solution was prepared directly in IMDM. ODQ was prepared in a NaOH 0.01% 10 mM stock solution prior to the correct dilution in IMDM. The percentage of DMSO in the final cell culture was within 0.04–0.12%.

4.3.3. Assessment of neutrophil apoptosis

Neutrophil apoptosis was primarily assessed by flow cytometry using a FACSscan (Becton Dickinson) as previously described. Annexin V was diluted 1/500 in the binding buffer (2.5 mL of 1 M CaCl2 in 500 mL HBSS) and 280 µL added to 20 µL of cells (5 × 10⁶/mL). Samples were then incubated on ice for 10 min protecting from light. Prior to analysis on the flow cytometer, 1 µL of PI (1 mg/mL) per sample was added. Data from the flow cytometry experiments were collected with Cell Quest Software and analysed with Flow Jo (Tree Star Inc., version 7.6). Statistical analysis was performed using Prism 5 (GraphPad Software, Inc., version 5.00). Apoptosis was also confirmed by cyto-centrifuging 80 µL of 5 × 10⁶/mL cells (300 rpm, 3 min), fixing the cells on the slide for 2 min in methanol and staining with Diff-Quick™ (Gamidor). Apoptotic morphology was assessed at 40× and 100× objective on a light microscope using standard criteria.

Acknowledgment

This work was supported in part by a Grant of the University of Turino 2008.

References and notes

1. Medzhitov, R. Nature 2008, 454, 428.
2. Gilroy, D. W.; Lawrence, T.; Perretti, M.; Rossi, A. G. Nat. Rev. Drug Disc. 2004, 3, 401.
3. Serhan, C.; Brain, S.; Buckley, C.; Gilroy, D.; Haslett, C.; O’Neill, L.; Perretti, M.; Rossi, A. G.; Wallace, J. FASEB J 2007, 21, 325.
4. Duffin, R.; Leitch, A.; Fox, S.; Haslett, C.; Rossi, A. G. Immunol. Rev. 2010, 236, 28.
5. Romano, M. Inflammation Allergy: Drug Targets 2006, 5, 81.
6. Serhan, C. N.; Petasis, N. A. Chem. Rev. 2011, 111, 5922.
7. Serhan, C. N.; Yang, R.; Martinod, K.; Kasuga, K.; Pillai, P. S.; Porter, T. F.; Oh, S. F.; Spite, M. J. Exp. Med. 2006, 206, 15.
8. El Kebir, D.; Filep, J. Sci. World J. 2011, 10, 1731.
9. Leitch, A. E.; Haslett, C.; Rossi, A. G. Br. J. Pharmacol. 2009, 158, 1004.
10. Knockaert, M.; Greengard, P.; Meijer, L. Trends Pharmacol. Sci. 2002, 23, 417.
11. Leitch, A.; Lucas, C.; Marwick, J.; Duffin, R.; Haslett, C.; Rossi, A. G. Cell Death Differ. 2012, 19, 1950.
12. Krystof, V.; Uldrijan, S. Curr. Drug Targets 2010, 11, 291.
13. Galons, H.; Oumata, N.; Meijer, L. Expert Opin. Ther. Pat. 2010, 20, 377.
14. Dekzeveld, M. F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kin, S. H. Eur. J. Biochem. 1997, 243, 518.
15. Rossi, A. G.; Sawatzky, D. A.; Walker, A.; Cheadle, T. A.; Niley, R. A.; Caldicott, A.; Martinez-Losa, M.; Walker, T. R.; Duffin, R.; Gray, M.; Crescenzi, E.; Martin, M. C.; Brady, H. J.; Savill, J. S.; Dransfield, I.; Haslett, C. Nat. Med. 2006, 12, 1056.
16. Kim, P. K. M.; Zamora, R.; Petrosko, P.; Billiar, T. R. *Int. Immunopharmacol.* **2001**, *1*, 1421.
17. Fortenberry, J. D.; Owens, M. L.; Brown, L. A. *S. Am. J. Physiol.: Lung Cell. Mol. Physiol.* **1999**, *276*, L435.
18. Singhal, P. C.; Patel, P.; Nahar, N.; Franki, N.; Kapasi, A.; Reddy, K.; Shah, N.; Nwakoby, I. E.; Mehrotra, B. J. *Leukocyte Biol.* **1999**, *66*, 930.
19. (a) Ward, C.; Wong, T. H.; Murray, J.; Rahman, I.; Haslett, C.; Chilvers, E. R.; Rossi, A. G. *Biochem. Pharmacol.* **2000**, *59*, 305; (b) Taylor, E.; Rossi, A.; Shaw, C.; Dal Rio, F.; Haslett, C.; Megson, I. *Br. J. Pharmacol.* **2004**, *143*, 179.
20. Taylor, E. L.; Megson, I. L.; Haslett, C.; Rossi, A. G. *Biochem. Biophys. Res. Commun.* **2001**, *289*, 1229.
21. Taylor, E. L.; Megson, I. L.; Haslett, C.; Rossi, A. G. *Cell Death Differ.* **2003**, *10*, 418.
22. Daiber, A.; Wenzel, P.; Oelze, M.; Munzel, T. *Clin. Res. Cardiol.* **2008**, *97*, 12.
23. Gasco, A.; Schoenafinger, K. In *Nitrile Oxide Donors*; Wang, P. G., Cai, T. B., Taniguchi, N., Eds.; WILEY-VCH Verlag GmbH & Co KGaA: Weinheim, 2005; pp 131–175.
24. Lucas, C. D.; Allen, K. C.; Dorward, D. A.; Hoodless, L. J.; Melrose, L. A.; Marwick, J. A.; Tucker, C. S.; Haslett, C.; Duffin, R.; Rossi, A. G. *FASEB J.* **2012**, http://dx.doi.org/10.1096/fj.12-218990.
25. (a) Oumata, N.; Ferandin, Y.; Meijer, L.; Galons, H. *Org. Process Res. Dev.* **2009**, *13*, 641; (b) Wang, S.; McClue, S.; Ferguson, J.; Hull, J.; Stokes, S.; Parson, S.; Westwood, R.; Fisher, P. *Tetrahedron: Asymmetry* **2001**, *12*, 2891.
26. Rivolta, R.; Aureli, R. *WO 2005/054175 A2*, 2005.
27. Matsuda, A.; Shinozaki, M.; Yamaguchi, T.; Homma, H.; Nomoto, R.; Miyasaka, T.; Watanabe, Y.; Abril, T. *J. Med. Chem.* **1992**, *35*, 241.
28. Vandromme, L.; Legcaverend, M.; Kremermann, S.; Lozach, O.; Meijer, L.; Grierson, D. *Bioorg. Med. Chem.* **2007**, *15*, 130.
29. Chichak, K.; Peters, A.; Cantrill, S.; Stoddard, J. *J. Org. Chem.* **2005**, *70*, 7956.
30. Shan, R.; Velazquez, C.; Knaus, E. *J. Med. Chem.* **2004**, *47*, 254.
31. Sastraraju, K.; Sastraraju, T.; Pyne, S.; Ung, A.; Jatisatsenr, A.; Lie, W. *J. Nat. Prod.* **2010**, *73*, 935.
32. Hannah, S.; Nadra, I.; Dransfield, I.; Pryde, J.; Rossi, A. G.; Haslett, C. *FEBS Lett.* **1998**, *421*, 141.
33. (a) Teixeira, M. M.; Fairbairn, S. M.; Norman, K. E.; Williams, T. J.; Rossi, A. G.; Hellewell, P. G. *Br. J. Pharmacol.* **1994**, *113*, 1363; (b) Shaw, C. A.; Webb, D. J.; Rossi, A. G.; Megson, I. *J. Inflamm. (Lond)* **2009**, *6*, 14.